Abstract
Purpose of ReviewWhile the Bruton's tyrosine kinase inhibitor (BTKi) ibrutinib has revolutionized the treatment of chronic lymphocytic leukemia (CLL),......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
